Gain Therapeutics Q3 loss narrows as R&D costs fall

Overview

• US biotech firm's Q3 net narrowed from prior year

• R&D and G&A expenses declined yr/yr, mainly due to lower rexaceract program costs

• Company reported long-term Phase 1b data showing no progression of Parkinson's motor symptoms

Outlook

• Company expects to initiate Phase 2 trial of rexaceract in Q1 2027

• Gain Therapeutics plans to select GT-04686 initial indication in Q4 2026

• Company anticipates additional clinical and regulatory milestones by year-end

Result Drivers

• LOWER R&D COSTS - Co said decrease in research and development expenses was mainly due to lower costs for rexaceract program and pipeline optimization, along with reduced personnel costs

• LOWER G&A EXPENSES - Co attributed lower general and administrative expenses to reduced professional fees and personnel costs

Company press release: ID:nGNX9nYChv

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Gain Therapeutics Inc is $8.00, about 633.9% above its November 9 closing price of $1.09

Reuters Recommended Reads

• Nov 10 - Biotech firm PepGen's Q3 net loss widens as R&D expenses rise

• Nov 10 - Ovid Therapeutics Q3 net loss widens as R&D spending rises

• Nov 9 - Perspective Therapeutics Q3 net loss widens on higher R&D costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)